Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Evotec AG

www.evotec.com

Latest From Evotec AG

Deal Watch: Celgene Joins Line Of Partners Tapping Exscientia’s AI-Driven Discovery Engine

While the proposed Bristol/Celgene merger nears an April vote, Celgene continues a recent spate of deal-making, paying $25m up front to Exscientia to discover small molecule candidates for cancer and autoimmune disease.

Business Strategies Commercial

Building A Biotech: Industry Veteran Moroney Reflects

Simon Moroney has led the German antibody technology biotech MorphoSys since 1992. Having taken the decision to retire just as the firm is entering the next phase in its evolution, he explains to Scrip why the time is right.

Europe Leadership

Evotec Extends Anti-Infectives Footprint With Helmholtz Collaboration

Building on a leading position in anti-infectives research, Evotec aims to develop a new class of antibacterials based on cystobactamids, which are found in slime bacteria and have potent activity against serious bacterial pathogens.

 

Infectious Diseases Research and Development Strategies

Venture Funding Deals: Vedanta Raises More Cash To Advance Microbiome Candidates

Cancer drug-developer Black Diamond emerges from stealth mode with Series A and closes Series B in the same month, while aging-focused Juvenescence closes its initial tranche and looks complete Series B by the end of the quarter. 

Deals Financing
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register